ANTENGENE CORP. DL-0001 - Asset Resilience Ratio
ANTENGENE CORP. DL-0001 (722) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ANTENGENE CORP. DL-0001's Asset Resilience Ratio has changed over time. See ANTENGENE CORP. DL-0001 (722) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ANTENGENE CORP. DL-0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 722 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €107.00K | 0.01% |
| Total Liquid Assets | €107.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: ANTENGENE CORP. DL-0001 maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ANTENGENE CORP. DL-0001 Industry Peers by Asset Resilience Ratio
Compare ANTENGENE CORP. DL-0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for ANTENGENE CORP. DL-0001 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ANTENGENE CORP. DL-0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €107.00K ≈ $125.09K |
€1.26 Billion ≈ $1.47 Billion |
+0.00pp |
| 2024-12-31 | 0.01% | €106.00K ≈ $123.93K |
€1.34 Billion ≈ $1.57 Billion |
+0.00pp |
| 2023-12-31 | 0.01% | €105.00K ≈ $122.76K |
€1.62 Billion ≈ $1.89 Billion |
+0.00pp |
| 2022-12-31 | 0.00% | €103.00K ≈ $120.42K |
€2.14 Billion ≈ $2.50 Billion |
-3.74pp |
| 2021-12-31 | 3.74% | €95.74 Million ≈ $111.93 Million |
€2.56 Billion ≈ $2.99 Billion |
-- |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more